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Abstract: Amplification of the HER2 gene and/or overexpression of its protein product have 
been found in up to 25% to 30% of human breast cancers and have been shown to be associ-
ated with poorer outcomes compared to ‘HER2 normal’ breast cancer. Research has focused 
on developing therapies directed to the HER2 receptor and its pathway. These include the 
monoclonal antibody trastuzumab, which has improved outcomes when used in patients with 
both advanced and early breast cancer. Lapatinib is a small-molecule tyrosine kinase inhibitor 
which has demonstrated activity in advanced breast cancer and is currently being evaluated in 
early stage disease. We discuss the therapeutic rationale and clinical trial experience with these 
agents. Other novel and emerging strategies targeting the HER2 receptor and its pathway are 
also discussed. These strategies include novel HER2 antibodies and small-molecule inhibitors, 
antibody–drug conjugates, agents targeting downstream components of the HER2 signaling 
pathway, and heat shock protein 90 (HSP90) inhibitors.
Keywords: HER2, human epidermal growth factor receptor 2, breast cancer, trastuzumab, 
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The human epidermal growth factor receptor 2 (HER2) gene, also known as c-erbB2 
and neu, encodes a 185-kDa transmembrane glycoprotein receptor. This receptor 
belongs to the ErbB family of growth factor receptors with intrinsic tyrosine kinase 
activity, the members of which exist in homodimer and heterodimer form when 
activated.1 Other members of the ErbB family are the epidermal growth factor recep-
tor 1 (EGFR/HER1), HER3 and HER4. Amplification of the HER2 gene and/or 
overexpression of its protein product have been found in up to 25% to 30% of human 
breast cancers2,3 and have been shown to be associated with poorer prognosis on multi-
variate analyses.4,5 In an effort to improve the outcomes of patients with HER2 positive 
(HER2+) breast cancer, research has focused on developing therapies directed to the 
HER2 receptor and its pathway. These therapies, which include the monoclonal anti-
body trastuzumab and the small molecule tyrosine kinase inhibitor lapatinib, as well as 
other novel and emerging strategies, will be discussed in this review. The mechanisms 
of action of the therapies discussed in this review are summarized in Table 1.
Trastuzumab
The initial HER2 targeting antibody was a murine monoclonal antibody targeting 
the extracellular domain IV of the receptor (muMAb 4D5), derived by immunizing 
mice with cells that expressed high levels of the HER2 protein product.6 In order to Biologics: Targets & Therapy 2009:3 290
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decrease the risks associated with the development of human 
antimouse antibodies, a humanized version (rhuMAb HER2 
or trastuzumab) was engineered by inserting the antigen-
binding residues of 4D5 into a cloned human immunoglobu-
lin G (IgG) framework.7 The mechanisms through which 
trastuzumab exerts its effects in vivo are not completely 
understood but are likely to include antibody-dependent cel-
lular cytotoxicity (ADCC),8 disruption of critical downstream 
proliferative signaling pathways and inhibition of cell cycle 
progression,9 and antiangiogenic effects.10 Some evidence 
suggests that downregulation of surface HER2 protein by 
endocytosis and degradation is a further mechanism of action 
of trastuzumab,11 although data are conflicting.12
Following extensive preclinical testing, a phase II study 
evaluated trastuzumab single agent therapy in 46 women with 
pretreated HER2+ metastatic breast cancer (MBC).13 HER2 
positivity was defined as those tumors in which at least 25% 
of cells exhibited characteristic membrane staining for the 
HER2 receptor. Based on preclinical data, trastuzumab was 
administered as a loading dose of 250 mg followed by 100 mg 
weekly for 10 weeks. The overall response rate (ORR) was 
11.6% and an additional 37% of patients achieved minimal 
responses or stable disease. This study provided the first 
clinical evidence for activity with an HER2 targeted therapy 
in breast cancer.
Subsequent larger multicenter phase II studies delivering 
weekly trastuzumab monotherapy for metastatic disease have 
confirmed these results. Cobleigh et al treated 222 women 
with HER2+ pretreated MBC with trastuzumab 4 mg/kg 
loading dose, followed by weekly infusions of 2 mg/kg.14 
HER2 positivity was defined in terms of the protein product 
by central laboratory immunohistochemistry (IHC) staining of 
2+ or 3+. The overall response rate in these pretreated patients 
was 15%, with a duration of response of 9.1 months.
Vogel et al enrolled 114 patients with previously 
untreated HER2+ MBC, randomizing patients between 
two dose schedules of trastuzumab: a 4 mg/kg loading dose 
followed by 2 mg/kg weekly as in the previous study, and 
a higher dose schedule using 8 mg/kg as a loading dose 
followed by 4 mg/kg weekly.15 The ORR in these patients 
was 26% with no difference in outcomes between the two 
dose schedules. Notably, the response rate for tumors staining 
3+ by IHC was 35%, with no responses seen in the group 
staining 2+. Retrospective HER2 gene amplification analysis 
by fluorescence in situ hybridization (FISH) was performed 
on a subset of women in this study: response rates of 34% 
were seen in the FISH-positive women compared with 7% 
in the FISH-negative women.
Pivotal trastuzumab trials for metastatic 
disease
The landmark phase III trial which led to the approval of 
trastuzumab for metastatic disease in combination with 
chemotherapy, enrolled 469 women with HER2+ MBC who 
were randomized to standard first-line chemotherapy or che-
motherapy plus trastuzumab.16 HER2 positivity was defined 
Table 1 Mechanisms of action of agents discussed
Drug Drug type Mechanism of action
Trastuzumab Monoclonal antibody against 
Her extracellular domain iv
Antibody-dependent cell-mediated cytotoxicity8
Disrupts downstream proliferative signaling pathways9
inhibits cell cycle progression9
Antiangiogenic effects10
endocytosis and degradation of Her211
Lapatinib Small molecule tyrosine kinase inhibitor 
of eGFr and Her2
inhibits receptors’ intrinsic tyrosine kinase activity48
Prevents downstream transmission of activation signal52
Tanespimycin Heat shock protein 90 (HSP90) inhibitor inhibits HSP90’s stabilizing effect on client proteins73–75
Facilitates Her2 degradation76,77
Pertuzumab Monoclonal antibody against Her2 
extracellular domain ii
Antibody dependent cell-mediated cytotoxicity87
Prevents Her2 heterodimerization87
Trastuzumab-
MCC-DM1
Antibody drug conjugate linking 
trastuzumab to microtubule cytotoxic
Targeted cytotoxic drug delivery90
Neratinib irreversible pan-erbB tyrosine kinase 
inhibitor
irreversibly inhibits tyrosine kinase activity of Her1, Her2 and Her495
Prevents downstream transmission of activation signal
Everolimus Small molecule serine-threonine kinase 
inhibitor of mTOr
inhibits proliferative signaling pathway downstream of Her296Biologics: Targets & Therapy 2009:3 291
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by IHC staining of 2+ or 3+, rather than by gene amplification. 
Standard chemotherapy consisted of an anthracycline (doxo-
rubicin or epirubicin) plus cyclophosphamide for those 
patients who had not been exposed to anthracyclines in the 
adjuvant setting, or paclitaxel for those who had previously 
received anthracyclines. Additionally, patients receiving 
chemotherapy alone could cross over to receive trastuzumab 
at the time of progression. Chemotherapy was administered 
every 3 weeks for 6 cycles (with an option of continuing at the 
investigator’s discretion) and trastuzumab was given weekly 
until progression of disease. The primary endpoint of the 
trial was time to progression (TTP), and this was prolonged 
from 4.6 to 7.4 months with the addition of trastuzumab to 
chemotherapy (P  0.001); there was also an improvement 
in the objective response rate from 32% to 50% (P  0.001), 
the median duration of response from 6.1 to 9.1 months 
(P  0.001) and a prolongation of median overall survival 
(OS) from 20.3 versus 25.1 months (P = 0.046) in favor of 
the trastuzumab arm. These clinical outcomes are particu-
larly striking given that 2/3 of the patients in the control arm 
crossed over to receive trastuzumab at the time of progres-
sion. These were the pivotal data that led to the approval of 
trastuzumab in combination with chemotherapy for the first 
line treatment of HER2+ MBC. A second randomized trial 
of docetaxel chemotherapy ± trastuzumab for a comparable 
cohort of patients produced similar results.17
A number of phase II studies have evaluated the addition 
of trastuzumab to different chemotherapy agents including 
docetaxel,18 paclitaxel,19 vinorelbine,20 capecitabine,21–23 
platinum agents24, 25 and gemcitabine26 with ORR ranging from 
20% to 68% and acceptable toxicity profiles. The definition of 
HER2 positivity varied for these trials, with some using IHC 
staining of 2+/3+ as eligibility criteria, and others stipulat-
ing IHC staining of 3+ and/or FISH positivity. Overall, these 
combinations represent viable salvage treatment options for 
patients with advanced stage HER2+ MBC.
Trastuzumab beyond progression?
A critical issue regarding the continued use of trastuzumab 
in the face of disease progression has only recently been 
addressed by prospective randomized data. Von Mincwitz 
and colleagues conducted a phase III trial of capecitabine vs 
capecitabine plus trastuzumab in patients with HER2+ MBC 
progressing on trastuzumab-containing therapy.27 Although 
accrual to this trial was halted early on the advice of an 
independent data monitoring committee with only 156 of 
a planned 482 patients enrolled, there was a significant 
improvement in progression-free survival (PFS) from 
5.6 months to 8.2 months in the trastuzumab arm at a median 
follow-up of 15.6 months (P = 0.03).
These were the first randomized data to show a benefit 
for the continuation of trastuzumab in spite of disease 
progression, lending credence to an approach that was previ-
ously widely adopted in common practice for the treatment 
of patients with HER2+ disease.
Adjuvant trastuzumab trials
The improvement in outcomes resulting from the addition 
of trastuzumab to chemotherapy in the metastatic setting 
led to its investigation as an adjunct to chemotherapy in the 
adjuvant arena. Four large multicenter randomized trials 
accrued thousands of patients, and reported interim outcome 
analyses in 2005: NSABP B-31, NCCTG N9831, HERA and 
BCIRG 006.28–30 In addition, two smaller studies designed to 
compare different chemotherapy regimens incorporated a ran-
domization to trastuzumab for HER2+ patients, and reported 
outcomes in subsequent years: FinHER and PACS 04.31,32 The 
study designs of these trials are summarized in Figure 1.
In the B-31 and N9831 trials, patients with early stage 
HER2+ breast cancer were all treated with a standard North 
American adjuvant chemotherapy regimen of 4 cycles 
of doxorubicin and cyclophosphamide (AC) followed by 
paclitaxel (T); half of these patients were randomized to 
additionally receive trastuzumab therapy for 1 year . Because 
of similarities in the design and patient populations of the two 
studies, a joint analysis of the data was undertaken, with the 
primary endpoint of evaluating disease-free survival (DFS).29 
In both trials trastuzumab was initiated with the taxane com-
ponent of chemotherapy in the investigational arm (a third 
arm of the N9831 study deferred trastuzumab until after the 
taxane). A combined total of 1833 patients were randomized 
to trastuzumab, with a control population of 1843 patients. 
Lymph-node positive patients only were enrolled, apart from 
191 ‘high-risk’ node-negative patients who were accrued to 
N9831 after a protocol amendment in May 2003. At a median 
follow-up of 2 years (2.4 years for B-31 and 1.5 years for 
N9831) there was a significant improvement in DFS for 
patients receiving trastuzumab, with a hazard ratio (HR) 
for first events of 0.48 (95% CI 0.39–0.59; P  0.0001). In 
addition, there was a 33% reduction in the risk of death in 
this group (HR 0.67, 95% CI 0.48-0.93; P = 0.015).
Simultaneously, a European multi-center trial (HERA) was 
evaluating the use of trastuzumab after chemotherapy in over 
5000 HER2+ patients.28 While the majority of patients in this 
study were also node-positive, approximately one third of the 
patients had node-negative tumors measuring at least 1 cm. Biologics: Targets & Therapy 2009:3 292
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The investigators randomized patients to either 1 or 2 years of 
trastuzumab versus observation after chemotherapy. A single 
chemotherapy regimen was not selected, but patients must have 
received a minimum of 4 cycles of predefined adjuvant and/or 
neoadjuvant therapy. The first interim analysis after only 1 year 
of median follow-up demonstrated a statistical improvement 
in DFS among patients receiving 1 year of trastuzumab com-
pared with observation, with a HR of 0.54 (95% CI 0.43–0.67; 
P  0.0001). At the second interim analysis with a median 
follow-up of 23.5 months, there was a statistically significant 
34% reduction in the risk of death (HR 0.66, 95% CI 0.47–0.91; 
P = 0.0115).33 Efficacy results for the 2-year trastuzumab arm 
are keenly awaited and are expected in 2009.
The BCIRG 006 study randomized 3222 HER2+ patients to 
3 arms: doxorubicin and cyclophosphamide (AC) for 4 cycles 
followed by docetaxel for 4 cycles; AC for 4 cycles followed 
by docetaxel for 4 cycles plus trastuzumab for 1 year; and 
a third novel arm lacking an anthracyline, of docetaxel plus 
carboplatin and trastuzumab, with trastuzumab continuing 
for 1 year. Based on preclinical data suggesting a synergistic 
effect of trastuzumab with platinum compounds, this study 
incorporated this third arm without anthracyclines to try and 
minimize cardiac risk. At an interim analysis performed at 
36 months of follow-up, the results demonstrated a significant 
improvement in DFS and OS for both trastuzumab containing 
arms compared to chemotherapy alone.34 The HR for DFS in 
the anthracycline-containing trastuzumab and nonanthracy-
cline arms compared to the control arm were 0.61 and 0.67, 
respectively; for OS, the HRs were 0.59 and 0.66, respectively. 
All results were statistically significant. Most importantly, the 
incidence of grade 3/4 cardiac toxicity with the novel nonan-
thracycline arm was similar to the control arm (0.4% vs 0.3%) 
and less than that of the anthracycline plus trastuzumab arm 
(2%). This was the fourth trial to confirm a significant reduction 
in the risk of recurrence with the addition of trastuzumab to 
chemotherapy for HER2+ early stage breast cancer, with the 
additional advantage of a minimally cardiotoxic chemotherapy 
regimen.
FinHER was a small study in which HER2+ patients (232 
in total) were randomized to a notably shorter duration of 
NSABP B31 NCCTG N9831
BCIRG 006
AC × 4
AC × 4
AC × 4
D × 4
D × 4, H × 52
DCarb × 6,  H × 52
AC × 4
T × 4
wT × 12
wT × 12
wT × 12 H × 52
H × 52
T × 4
H × 1 year
H × 2 year
H × 52
R
R
R R R
R
R
HERA
STANDARD
CHEMOTHERAPY
No H
FinHER PACS04
D × 9  weeks
D + H × 9  weeks
V + H × 9  weeks
V × 9  weeks
FEC × 3 
No H
FEC100 × 6
ED × 6
H × 1 year
HER2+
Figure 1 Study designs of the adjuvant trastuzumab trials.
Abbreviations: AC, doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 every 3 weeks; T, paclitaxel 175 mg/m2 every 3 weeks; H, trastuzumab 4 mg/kg loading 
dose followed by 2 mg/kg weekly × 51 weeks; wT, weekly paclitaxel 80 mg/m2; D, docetaxel 100 mg/m2 every 3 weeks; DCarb, docetaxel 75 mg/m2 + carboplatin AUC6 
every 3 weeks; v, vinorelbine 25 mg/m2 Day 1, 8 and 15 every 3 weeks; FEC, fluorouracil 600 mg/m2, epirubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 every 
3 weeks; FEC100, fluorouracil 500 mg/m2, epirubicin 100 mg/m2 plus cyclophosphamide 500 mg/m2 every 3 weeks; eD, epirubicin 75 mg/m2 plus docetaxel 75 mg/m2 
every 3 weeks.Biologics: Targets & Therapy 2009:3 293
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trastuzumab therapy (9 weekly doses) in combination with 
either docetaxel or vinorelbine or to these chemotherapy 
agents alone.31 All patients then proceeded to 3 cycles of 
anthracycline-containing chemotherapy. This study was pow-
ered to detect a 50% to 67% improvement in recurrence-free 
survival in the HER2+ patients treated with trastuzumab, at a 
power of 0.80. In spite of this threshold, the study achieved 
this aim with a HR for recurrence of 0.42 (95% CI 0.21–0.83; 
P = 0.01) and a HR for death of 0.41 (95% CI 0.16–1.08; 
P = 0.07). Although the study was small, it achieved simi-
lar levels of risk reduction as seen with 1 year of adjuvant 
trastuzumab, and raised the question of duration for the 
antibody in this setting. While currently 1 year of adjuvant 
trastuzumab remains the standard of care for HER2+ early 
breast cancer, results from the 2-year arm of the HERA trial 
and the ongoing Greek35 and French36 studies randomizing 
patients to 6 vs 12 months of trastuzumab in the adjuvant 
setting may help define the optimal duration of treatment.
The lone trial that has not shown an advantage for 
trastuzumab in the adjuvant setting is the PACS 04 trial in 
which 528 HER2+ patients were randomized to 1 year of 
trastuzumab or observation after completion of adjuvant 
chemotherapy.32 Although there was a trend for benefit in the 
first 18 months, in the intent-to-treat analysis after a median 
follow-up of 48 months, there was no significant difference 
observed in either the DFS or OS between the trastuzumab and 
the observation arms. The small study size, statistical power, 
and sequential versus concurrent administration of the trastu-
zumab in this trial have been raised as possible explanations 
for this negative result; additional studies and further followup 
of the 4 large randomized trials and other ongoing studies may 
help to place these provocative data in context.
Trastuzumab toxicity
It was not immediately apparent from the early clinical 
trials with trastuzumab that cardiac toxicity would be a 
major concern with this agent. Rates of cardiac dysfunc-
tion in the two major studies of trastuzumab monotherapy 
(as defined by congestive heart failure, cardiomyopathy or 
left ventricular ejection fraction (LVEF) decline 10% 
points) were relatively modest at 2% to 4.7%.14,15 However, 
in the landmark phase III trial with chemotherapy, the use 
of trastuzumab concurrently with anthracyclines appeared 
to dramatically increase the rate of cardiac dysfunction, 
from 8% in the anthracycline chemotherapy group to 27% 
in the anthracycline and trastuzumab group.16 Accordingly, 
concurrent use of anthracyclines and trastuzumab is not 
advised, apart from the neoadjuvant setting where there is 
limited experience demonstrating safety and efficacy for 
concurrent administration.
Given the potential for cardiac dysfunction, there was 
rigorous cardiac monitoring as part of the adjuvant trastu-
zumab trials which has allowed for prospective monitoring 
and evaluation of this toxicity. After 5 years of follow-up, 
there was a 4% incidence of class III/IV congestive heart 
failure (CHF) or cardiac death in the patients receiving 
trastuzumab on the adjuvant B31 trial.37 A detailed cardiac 
safety analysis of this trial revealed that trastuzumab was 
discontinued for asymptomatic decreases in LVEF in 14% 
of evaluable patients.38 Of those who had a repeat LVEF 
assessment at 6 months after discontinuation, only 25% 
had an LVEF value persistently below 50%. Similarly, in 
BCIRG 006 17.3% of patients receiving AC-TH sustained 
a 10% decline in LVEF relative to baseline, with 26% of 
patients who had repeat assessments after 42 days demon-
strating persistent declines.37 Hence, the majority of patients 
will experience improved cardiac function with or without 
appropriate medications for CHF, suggesting a reversibility 
to the cardiac dysfunction induced by trastuzumab and dis-
tinguishing it from the damage imposed by anthracyclines 
which is largely irreversible.39
And while the underlying mechanism of trastuzumab-
induced cardiotoxicity is not well understood, animal 
studies have suggested an important role for HER2 signal-
ing pathways in embryonic heart development, and in the 
prevention of dilated cardiomyopathy.40 Thus signaling 
through the HER2 pathway may be important for cardiac 
myocyte survival during periods of stress. In the absence of 
preventative measures, cardiac monitoring is imperative for 
patients on trastuzumab, particularly in the adjuvant setting 
where left ventricular function must be monitored every 
3 to 4 months.
Beyond cardiac toxicity, trastuzumab is rarely associated 
with typical chemotherapy-type side effects. The most com-
mon noncardiac toxicity is infusion reactions, which were seen 
in 25% of patients during the first infusion in the landmark 
study in combination with chemotherapy, and generally did 
not recur on subsequent infusions.16 Grade 3 and 4 infusion 
reactions were not seen in the adjuvant trastuzumab studies, 
perhaps due to careful pre-medication and monitoring of 
patients. A rare but notable toxicity encountered in the NSABP 
B31 and NCCTG N9831 studies was interstitial pneumoni-
tis, which was fatal in 1 patient in each study.29 Additional 
adverse events encountered with trastuzumab alone or with 
chemotherapy in clinical trials for early and advanced breast 
cancer include arthralgia, myalgia, fatigue, dyspnea, nail Biologics: Targets & Therapy 2009:3 294
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changes, rash, headache, insomnia, thrombosis/embolism, 
and diarrhea,41 with grades 3 and 4 of any of these toxicities 
occurring in under 1% of patients receiving trastuzumab after 
adjuvant chemotherapy in the HERA study.28 The incidence of 
grade 4–5 neutropenia was increased from 0.7% to 2% when 
trastuzumab was added to chemotherapy in the NCCTG N9831 
adjuvant study, and grade 3–5 infections/febrile neutropenia 
were increased from 1.4% to 3.3%.41 Anemia is also seen with 
trastuzumab, with 1% of patients receiving trastuzumab as 
a single agent for MBC experiencing grade 3 anemia.14 Rare 
cases of glomerulopathy causing nephrotic syndrome have 
also been reported in the postmarketing setting.41
Trastuzumab: mechanisms of resistance
In spite of its success in the treatment of both early and advanced 
stage HER2+ breast cancer, a proportion of patients who receive 
trastuzumab-containing adjuvant therapy will relapse and nearly 
all patients receiving trastuzumab for metastatic disease will 
experience progression. A number of potential mechanisms 
underlying trastuzumab resistance have been proposed and 
include inhibition of the interaction of trastuzumab with its target 
protein by increased expression of the membrane glycoprotein 
MUC442 or shedding of the extracellular domain of the receptor 
leaving behind the truncated form of the receptor (p95) which 
retains kinase activity but cannot bind to trastuzumab. In an 
analysis of 46 patients with HER2+ MBC, p95 expression in 
the tumors was associated with clinical trastuzumab resistance.43 
Cross talk or heterodimerization between HER2 and IGF-1R42 
or HER family members44 may be another potential mechanism 
of resistance to trastuzumab. In these cases, signaling through 
other growth factor receptors may lead to the same downstream 
activation of the PI3K pathway resulting in cell proliferation. 
Looking at the pathway itself, activating mutations AKT and 
decreased levels of PTEN expression have also has been 
associated with trastuzumab resistance.45,46 Other potential 
mechanisms of resistance explored in preclinical models include 
downregulation of a cyclin-dependent kinase (p27kip1), a down-
stream effector of multiple growth factor receptor pathways,47 
and transcriptional upregulation of HER2 gene expression.48 
Ultimately, a clear and better understanding of the molecular 
mechanisms of resistance to trastuzumab will allow clinicians to 
identify the optimal treatment strategies for individual patients 
with HER2+ disease.
Lapatinib
As described above, de novo and acquired trastuzumab 
resistance are major clinical problems. Hence, new agents 
targeting this growth signaling pathway are urgently needed. 
The first of this new generation of HER2 targeting drugs, 
lapatinib (Tykerb®/Tyverb®), was approved for the treatment 
of HER2+ MBC by the US Food and Drug Administration 
(FDA) in 2007. Lapatinib, previously known as GW572016, 
is a reversible small-molecule tyrosine kinase inhibitor 
which targets both HER2 and EGFR tyrosine kinases and 
has the advantage of being administered orally. In vitro 
studies demonstrated superior growth-inhibitory effects 
for this molecule in HER2 and EGFR overexpressing cell 
lines.49 Additionally, lapatinib can inhibit the growth of 
HER2+ human breast cancer cells that are resistant to the 
effects of trastuzumab,50 as well as enhance the activity of 
anti-HER2 antibodies when used together.51 Activity in vivo 
was confirmed in HER2+ human breast carcinoma xenografts 
in mice.49,52 Inhibition of activation of downstream signaling 
molecules was also demonstrated in human tumor xenograft 
models.53
Lapatinib trials
The first human studies of lapatinib were two phase I 
pharmacokinetic studies testing low doses of the drug in 
healthy subjects. Peak serum concentrations were detected 
at a median of 3 hours after the dose, with steady state con-
centrations being achieved at 6 to 7 days. The most common 
toxicities encountered in these healthy volunteers were 
headache, diarrhea, rash, cold symptoms, gastrointestinal 
symptoms and elevation of liver enzymes.54 A subsequent 
phase I study evaluated the safety of lapatinib in 64 patients 
with solid tumors (including 4 with breast cancer).55–57 
39 patients received once daily dosing at doses ranging 
from 175 to 1800 mg daily. Twenty-five patients received 
doses of 500 mg, 750 mg or 900 mg twice daily. The most 
commonly encountered toxicities in all cohorts were tran-
sient grade 1–2 rash, diarrhea, nausea/vomiting, fatigue and 
anorexia. Grade 3 diarrhea was seen in 2 of 6 patients at 
900 mg bid, requiring dose reductions. A complete tumor 
remission was seen in 1 patient with EGFR overexpressing 
squamous cell carcinoma of the head and neck; in addition 
22 patients experienced stable disease with a median dura-
tion of 4 months. All of the patients who continued therapy 
beyond 4 months were on daily doses of at least 1200 mg. 
The authors concluded that daily lapatinib dosing was 
well tolerated with evidence of clinical activity. Another 
phase I study evaluated 5 once daily dose cohorts in a more 
selected population of 67 patients with EGFR and/or HER2 
overexpressing metastatic cancers.58 Daily doses ranged 
from 500 mg to 1600 mg. Lapatinib was generally well 
tolerated, with the most common toxicities being diarrhea in Biologics: Targets & Therapy 2009:3 295
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42% and rash in 31%. The incidence of diarrhea was found 
to be increased with increasing dose. There were 4 partial 
responses (PRs), all of which were documented in patients 
with trastuzumab-resistant MBC (including 2 patients with 
inflammatory breast cancer).
A number of phase II studies followed, evaluating lapatinib 
monotherapy in HER2+ patients with advanced breast cancer. 
In the first of these, 140 patients with HER2-overexpressing 
and 89 with HER2 negative advanced breast cancer were 
treated with lapatinib 1500 mg daily.59 This was a heavily pre-
treated population, 76% of patients having received 4 or more 
lines of prior chemotherapy. There were no responses seen in 
the HER2– cohort. The HER2+ cohort appeared to derive a 
slight benefit, however, with an ORR of 4.3% as determined 
by the investigators, and 1.4% as determined by the indepen-
dent review committee. In a phase II study of HER2+ patients 
only, 78 patients who had progressed on prior trastuzumab 
therapy were randomly allocated to lapatinib as a single agent 
at 1250 mg or 1500 mg daily.60 The ORR was again relatively 
low in this study, at 7.7% by investigator interpretation and 
5.1% as per the independent review committee. The time to 
progression was 15.3 weeks.
The EGF20009 study evaluated lapatinib monotherapy in a 
first-line setting.61 138 patients who were previously untreated 
in the metastatic setting were randomized to 1500 mg orally 
daily or 500 mg twice daily. All patients were required to be 
HER2+ by FISH analysis; HER2 protein expression was not 
evaluated. No patients had received prior trastuzumab. Results 
were more impressive in this cohort of patients, with an ORR 
of 24%. By indirect comparison this result compares favor-
ably with the ORR of 34% in the subgroup of women with 
HER2 FISH-amplified MBC treated in a phase II study of 
upfront trastuzumab monotherapy.15 The PFS rate at 4 months 
in the lapatinib study was 63%, and 43% at 6 months.61 There 
were no significant differences in outcomes between the two 
dosing groups. The common toxicities reported by investiga-
tors to be lapatinib-related were diarrhea (36%), rash (27%), 
pruritus (18%) and nausea (10%).
randomized lapatinib trials
Two large randomized phase III studies investigated the 
addition of lapatinib to chemotherapy regimens for advanced 
breast cancer. EGF100151 was an open-label study which 
enrolled patients with HER2+ advanced breast cancer who had 
received previous anthracycline, taxane and trastuzumab.62,63 
The control arm received capecitabine 2500 mg/m2 daily for 
14 days on a 21-day cycle. The investigational arm received 
a lower daily dose of capecitabine (2000 mg/m2) on the same 
schedule, with oral lapatinib at 1250 mg daily continuously. 
Study enrollment began on March 29th, 2004. A data lock-in 
was performed in November 2005, based on a pre-specified 
event threshold. The outcomes of the 324 women who had 
been accrued to date were subject to an interim analysis, 
following which the data safety monitoring committee recom-
mended reporting the study results and offering lapatinib to 
women who had been receiving capecitabine monotherapy on 
the control arm. This was based on a significant improvement 
in the primary study endpoint of time to progression (TTP), 
with a HR of 0.49 (95% CI 0.34–0.71, P  0.001)62 with the 
combination treatment; additionally TTP was 8.4 months 
versus 4.4 months in favor of the lapatinib arm. There were no 
significant differences in response rate or survival. An updated 
analysis included all 399 women who had entered the trial 
before accrual was closed in April 2006. In this analysis, TTP 
remained significantly prolonged in the lapatinib combina-
tion group (6.2 vs 4.3 months, HR 0.57; 95% CI 0.43–0.77, 
P  0.001);63 the ORR was also significantly higher for the 
combination (24% vs 14%, P = 0.017). In an exploratory 
analysis, the frequency of central nervous system (CNS) 
as site of first progression was lower in the lapatinib arm 
(4 vs 13, P = 0.045). Not surprisingly given the individual 
toxicity profiles of capecitabine and lapatinib, diarrhea was 
the most common toxicity for the combination, occurring 
in 60% of patients. 12% experienced grade 3 diarrhea, and 
1% grade 4. Other toxicities commonly encountered in the 
combination arm were hand foot syndrome (49%), rash 
(27%), nausea (44%), vomiting (26%) and fatigue (18%). 
The results of this trial were the basis for the approval of 
lapatinib by the FDA.
The other phase III study of lapatinib in combination 
with chemotherapy (EGF30001) was a randomized, placebo-
controlled study that examined the impact of adding lapatinib 
to paclitaxel as first-line therapy of advanced breast cancer.64 
In contrast to the capecitabine study, HER2 negative and 
HER2 uncharacterized patients were enrolled onto this 
study. No patients had known HER2+ disease at study entry, 
although it was expected that a proportion would turn out to 
be HER2+ on testing. The paclitaxel dose was 175 mg/m2 
by intravenous infusion every 3 weeks, and patients were 
randomized to either lapatinib 1500 mg or placebo daily. In 
the intent-to-treat population of 579 patients, the response 
rate was higher for the combination arm (35% vs 25%, odds 
ratio = 1.7; 95% CI, 1.1–2.4; P = 0.008); however there were 
no significant difference in TTP, event-free survival (EFS) or 
OS. 86 patients on this study were found to have HER2+ MBC 
and the addition of lapatinib for this group was associated Biologics: Targets & Therapy 2009:3 296
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with a longer median TTP of 36.4 vs 25.1 weeks, with a HR 
for progression of 0.53 (95% CI, 0.31–0.89, P = 0.005). EFS, 
ORR and clinical benefit rate (CBR) were also significantly 
better with combined therapy in the HER2+ subpopulation. 
Conversely, there was no advantage in any of the efficacy 
endpoints in the HER2 negative patients. The addition of 
lapatinib to paclitaxel was associated with significantly higher 
rates of rash, diarrhea, mucositis and vomiting. Furthermore, 
there was an increased rate of fatal adverse events in the 
paclitaxel/lapatinib group (8 patients, 2.7%) compared to 
the paclitaxel/placebo group (2 patients, 0.6%). The fatal 
adverse events in the lapatinib group included three cases of 
sepsis associated with diarrhea, mostly occurring early in the 
course of the trial before the investigators instituted aggressive 
measures to proactively manage diarrhea. The results of this 
study showed that HER2 negative unknown patients do not 
benefit from the addition of lapatinib to paclitaxel.
Lapatinib has also been combined with endocrine therapy 
for MBC, based on the pre-clinical evidence for cross-talk 
between growth factor receptor (such as HER2 and EGFR) 
and hormone receptor pathways as a potential mechanism 
for endocrine resistance.65 Results of the EGF30008 study 
were presented at the San Antonio Breast Cancer Symposium 
in December 2008.66 This study randomized 1208 patients 
with MBC to letrozole 2.5 mg daily with either lapatinib 
1500 mg daily or placebo. Of the 219 patients in this study 
who had HER2+ disease, the addition of lapatinib to letrozole 
improved PFS from 3.0 months to 8.2 months (HR = 0.71; 
95% CI, 0.53–0.96, stratified log-rank P = 0.019) and response 
rates (from 28.7% to 47.7%). No effect on PFS or response 
rate was seen in the HER2 negative patients although an 
exploratory Cox regression analysis suggested a PFS benefit 
for lapatinib, in patients with recent tamoxifen treatment 
(representing endocrine resistance) as an important covariate. 
The combination treatment was well tolerated, with no 
unexpected toxicities and a low rate of asymptomatic LVEF 
decline (2%). A similar result was observed in the TAnDEM 
trial which randomized 208 patients with HER2+ MBC to 
first-line therapy with anastrozole ± trastuzumab.67 Outcomes 
were superior with the combination arm in terms of PFS 
(4.8 vs 2.4 months, P = 0.0016), ORR (20.3% vs 6.8 %, 
P = 0.018), and CBR (42.7% vs 27.9%, P = 0.026). Although 
there was a trend in OS favoring the combination arm, it was 
not statistically significant (28.5 vs 23.9 months, P = 0.325). 
About 70% of the patients in the anastrozole only group 
crossed over to receive trastuzumab upon progression of 
disease, and the OS was the same in this group as in those 
who received the upfront combination.
O’Shaughnessy et al have reported results from a 
randomized trial of lapatinib alone versus lapatinib plus 
trastuzumab in patients with HER2+ MBC who progressed 
on trastuzumab.68 Patients were treated with either lapatinib 
at 1500 mg daily or lapatinib at 1000 mg daily plus weekly 
conventional trastuzumab. If patients progressed on the 
lapatinib monotherapy arm, they could cross over to the 
lapatinib plus trastuzumab regimen. 296 pts were randomized 
and results revealed a progression free survival advantage 
in favor of the combination of 12 weeks versus 8.4 weeks 
(P = 0.029) and an improvement in the clinical benefit rate 
of 25.2 vs 13.2 weeks (P = 0.02); response rate and overall 
survival were similar in both arms. Both treatment regimens 
were generally well tolerated. The improved clinical outcome 
achieved with the combination of lapatinib and trastuzumab 
in patients progressing on trastuzumab-based therapy further 
confirms the role for continued trastuzumab in spite of pro-
gression and additionally supports a role for dual modality 
HER2 inhibition.
Lapatinib in CNS disease
Given its large molecular size, trastuzumab is unable to 
cross the blood–brain barrier (BBB) effectively. This is of 
particular concern, given the frequency of CNS metastases 
in HER2+ MBC. In a report by Bendell et al 34% of patients 
with HER2+ MBC developed CNS metastases at a median 
of 6 months from the initiation of trastuzumab therapy 
for metastatic disease, with 50% of these patients having 
stable or responding disease outside the CNS at the time.69 
Furthermore, half of the patients with CNS metastases died 
as a result of progressive CNS disease, rather than systemic 
disease. Conversely, lapatinib has been shown to reduce the 
formation of large brain metastases in a mouse xenograft 
model using a trastuzumab-resistant HER2+ MBC line.70 
A phase II study of lapatinib monotherapy in 241 patients 
with progressive brain metastases after trastuzumab and 
radiotherapy demonstrated a disappointing response rate of 
2.6%,71 however the authors noted that 18% of patients were 
progression-free at 16 weeks, and reported some favorable 
volumetric changes in CNS disease based on exploratory 
analysis. Further prospective evaluation of the role of lapa-
tinib in the prevention of CNS disease will be explored in the 
adjuvant studies of lapatinib that are currently underway.
Adjuvant lapatinib trials
The Adjuvant Lapatinib and/or Trastuzumab Treatment Opti-
mization (ALTTO) study is an ongoing, four arm randomized 
study evaluating lapatinib (arm A), trastuzumab (arm B), Biologics: Targets & Therapy 2009:3 297
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trastuzumab followed by lapatinib (arm C), or concurrent 
treatment with both agents (arm D) for early stage HER2+ 
breast cancer.72 Two trial designs are available: In design 1, 
patients will be randomized to one of the four anti-HER2 
treatment strategies described above after completing adju-
vant anthracycline-containing chemotherapy; in design 2, the 
anti-HER2 therapy will commence concurrently with pacli-
taxel, after surgery and anthracycline-based chemotherapy. 
A sister trial, neo-ALTTO, will test the anti-HER2 regimens 
in the neoadjuvant setting. An unexpected toxicity of grade 3 
diarrhea seen with the concurrent paclitaxel/trastuzumab/
lapatinib combination was observed in a pilot study of this 
combination following dose-dense AC, where lapatinib was 
given at a dose of 1000 mg daily. This combination was not 
feasible with 34% of patients requiring a lapatinib dose-
reduction, predominantly due to grade 3 diarrhea73. These 
findings led to a modification of the lapatinib dose on the 
corresponding arm of ALTTO trial (design 2, arm D).
Other HER2 therapies
HSP90 inhibitors
Heat shock protein 90 (HSP90) is a molecular chaperone 
which plays an important role in the maturation and con-
formational stabilization of a number of cellular ‘client’ 
proteins. When HSP90 is inhibited its clients are rendered 
unstable and ultimately they undergo degradation in the 
proteasome.74–76 One of the most sensitive client proteins of 
Hsp90 inhibition is HER2.77,78
Tanespimycin (17AAG, 17-allylamino-17-demethox-
ygeldanamycin), a geldanamycin derivative, is the lead 
Hsp90 inhibitor in clinical development and inhibits Hsp90 
function in tumors in a variety of murine models, and it has 
now been extensively studied as a single agent in patients 
with solid tumors in early phase clinical trials.79–85 A phase I 
study of the combination of tanespimycin and trastuzumab 
enrolled 25 patients with advanced solid tumors, with 15 of 
these patients having HER2+ MBC.86 Tanespimycin was 
administered on a weekly schedule in escalating dose cohorts 
in combination with weekly conventional trastuzumab. The 
recommended phase 2 dose for tanespimycin was determined 
to be 450 mg/m2 weekly. The most commonly encountered 
toxicities were grade 1–2 vomiting, diarrhea, headache, 
fatigue and anorexia. Of note, no significant cardiotoxic-
ity was encountered. Tumor regressions were observed 
in 5 patients, all of whom had HER2+ MBC previously 
progressing on trastuzumab. These results led to a phase 
2 study of this combination in patients with HER2+ MBC 
progressing on one line of trastuzumab-based therapy. 
When interim data from this study was presented at the 
annual meeting of the American Society of Clinical Oncology 
(ASCO) 2008, a total of 31 patients had been enrolled, with 
27 of these evaluable for response.87 There were 7 patients 
with RECIST-defined partial responses (one unconfirmed) 
and an additional 5 patients with objective tumor regression 
measuring between 20% to 29% reduction in tumor burden; 
5 patients also had disease stabilization for 4 months. 
The overall response rate was 26% with a clinical benefit 
rate of 63%. Based on these clinical results, the combina-
tion of tanespimycin plus trastuzumab is highly active for 
trastuzumab-treated HER2+ MBC. A number of other HSP90 
inhibitor compounds are also undergoing clinical evaluation 
for HER2+ MBC.
Other HER2 antibodies
Pertuzumab (Omnitarg®; Genentech) is a humanized mono-
clonal antibody that binds to the extracellular domain II of 
the HER2 receptor, preventing receptor dimerization and 
ligand-activated signaling with other growth factor receptors, 
including other HER family members.88 In a phase II study of 
pertuzumab plus trastuzumab, 66 patients with HER2+ MBC 
progressing on trastuzumab were enrolled and treated with 
3-weekly pertuzumab and weekly or 3-weekly trastuzumab.89 
Interim results presented at the ASCO 2008 meeting revealed 
a RR of 24.2%, with a CBR of 50%. The most frequently 
encountered toxicities were grade 1 and 2 diarrhea (64%), 
fatigue (33%), nausea (27%), rash (26%) and headache 
(20%). Only 3 patients had an LVEF which declined by more 
than 10% from baseline to a level less than 50%. Currently a 
double-blind multicenter phase III study, CLEOPATRA, is 
randomizing patients to docetaxel plus trastuzumab versus 
docetaxel plus trastuzumab and pertuzumab as first-line 
treatment for HER2+ advanced breast cancer.90
Antibody–drug conjugates
A promising strategy involves coupling targeted antibodies 
with potent antitumor agents, in the form of antibody-drug 
conjugates (ADC). Trastuzumab-MCC-DM1 (T-DM1) is an 
ADC using a stable thioether linkage to couple trastuzumab to 
a derivative of maytansine, a chemotherapeutic agent with a 
microtubule-binding effect similar to vinca alkaloids. T-DM1 
has antitumor activity in trastuzumab-sensitive and trastu-
zumab-resistant preclinical models of HER2+ breast cancer.91 
A phase I study evaluated 3-weekly dosing of T-DM1 in 
patients with HER2+ MBC progressing on trastuzumab.92 
Tumor responses were seen in 5 of 9 patients (4 confirmed, 
44%) at the maximally tolerated dose (MTD) of 3.6 mg/kg. Biologics: Targets & Therapy 2009:3 298
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A rapidly reversible thrombocytopenia (which was grade 4 
in two patients) was the dose-limiting toxicity. There was 
no evidence of deleterious cardiac effects. Subsequently a 
weekly dosing schedule achieved an MTD of 2.4 mg/kg.93 
For this schedule, 9 of 15 evaluable patients had confirmed 
PRs (53%). Interim results of a phase II study of 3-weekly 
T-DM1 as third-line therapy for patients with HER2+ MBC 
progressing on prior trastuzumab, were presented in 2008.94 
107 of 122 enrolled patients were evaluable for efficacy, 
with a median follow-up of 4.4 months. 55% of patients 
had received prior lapatinib. There was no grade 3 or 4 
cardiac dysfunction reported. The confirmed response rate 
in evaluable patients was 27.1%, and in lapatinib pretreated 
patients was 21.7%. Further phase II studies are now under-
way, including a randomized comparison of T-DM1 versus 
the combination of trastuzumab and docetaxel as first-line 
therapy for HER2+ MBC3 and a randomized phase III trial 
of T-DM1 versus capecitabine plus lapatinib.32
Other small-molecule inhibitors 
of HER2 signaling
Neratinib is a low-molecular-weight pan-erbB tyrosine 
kinase inhibitor. In contrast to lapatinib, it irreversibly inhib-
its erbB1 and erbB2. It has been evaluated in trastuzumab 
pretreated and trastuzumab-naive patients in a phase II clini-
cal trial.95 A daily dose of 240 mg orally was used based on 
a dose-limiting toxicity of diarrhea encountered in the phase 
I setting. All patients had HER2 status centrally confirmed 
by FISH testing. The ORR was 26% for patients who had 
received prior trastuzumab, with a median PFS of 23 weeks. 
The trastuzumab-naive patients had an ORR of 56%, with a 
median PFS of 40 weeks. The major toxicity encountered was 
diarrhea, occurring in 97% of patients who had received prior 
trastuzumab, with a grade 3 or 4 rate of 30% in this group 
(13% in the trastuzumab naive patients). This agent is now 
undergoing evaluation in a phase III randomized trial.
mTOR inhibitors
Loss of expression of the tumor suppressor PTEN and/or 
activation of the PI3K/AKT signalling proteins have been 
reported as possible mechanisms of resistance to trastuzumab.96 
Mammalian target of rapamycin (mTOR) is a serine-threonine 
kinase which is a downstream component of the PTEN/PI3K 
pathway. Everolimus (RAD001) is an oral inhibitor of mTOR 
which has been evaluated with combinations of trastuzumab 
and various chemotherapy agents in phase I studies. Two 
studies reported updated analyses at SABCS 2008. Everolimus 
on a daily or weekly schedule was combined with weekly 
trastuzumab and either weekly paclitaxel97 or vinorelbine.98 
Both studies enrolled patients with HER2+ MBC progressing 
on or after trastuzumab. The most common dose-limiting tox-
icities were neutropenia and stomatitis. Nine partial responses 
were seen among 27 evaluable patients with paclitaxel (41%), 
and 6 responses among 37 patients with vinorelbine (18%). 
Phase II studies are awaited.
Conclusion
Clinical studies have confirmed that trastuzumab significantly 
enhances the outcomes for subsets of patients with both 
early and late stage HER2+ breast cancer. Moreover, the 
HER2 receptor remains a viable target in spite of progres-
sion and is a relevant target for novel anti-HER2 strategies. 
Lapatinib is approved as the next line of HER2 therapy after 
progression on trastuzumab and other promising agents in 
clinical development include antibody conjugates and heat 
shock protein 90 inhibitors among others. Understanding the 
mechanisms and biochemistry of disease development and 
progression and targeting the specific pathways and critical 
proteins to the process will allow us to build on our current 
anticancer strategies. Trastuzumab has rightly been consid-
ered a landmark; perhaps someday it will be looked on as 
the first stepping stone across a wide stream.
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